Home > Boards > US Listed > Biotechs > Anavex Life Sciences Corp (AVXL)

So, I’m in or about to enter into

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
jtsmgoblue Member Profile
 
Followed By 3
Posts 638
Boards Moderated 0
Alias Born 03/15/10
160x600 placeholder
Anavex Life Sciences Issued New U.S. Patent for ANAVEX®2-73 Treatment of Neurodevelopmental Disorders including Rett Syndrom... GlobeNewswire Inc. - 1/8/2020 7:00:10 AM
Anavex Life Sciences Reports Fiscal Year 2019 Financial Results And Provides Clinical Study Updates GlobeNewswire Inc. - 12/16/2019 7:00:10 AM
Anavex Life Sciences to Announce Fiscal 2019 Year End Financial Results on Monday December 16, 2019 GlobeNewswire Inc. - 12/10/2019 7:00:10 AM
Citation Growth Corp. (OTCQX: CGOTF) Weathering the Cannabis Downturn InvestorsHub NewsWire - 12/9/2019 7:23:11 AM
Anavex Life Sciences Presents ANAVEX®2-73 (blarcamesine) Data at 12th Clinical Trials on Alzheimer's Disease (CTAD) 2019 Con... GlobeNewswire Inc. - 12/4/2019 7:00:10 AM
Anavex Life Sciences Receives Rare Pediatric Disease Designation from FDA for ANAVEX®2-73 (blarcamesine) for the Treatment o... GlobeNewswire Inc. - 11/14/2019 7:00:00 AM
Anavex Life Sciences Announces Publication of Foundational Data for ANAVEX®2-73 (blarcamesine) in Rett Syndrome GlobeNewswire Inc. - 11/6/2019 7:00:00 AM
Anavex Life Sciences Announces ATTENTION-AD ANAVEX®2-73 Extension Clinical Study in Early Alzheimer’s Disease GlobeNewswire Inc. - 10/9/2019 7:00:00 AM
Anavex Life Sciences Issued New U.S. Patent for Composition of Matter Covering ANAVEX®2-73 for the Treatment of Alzheimer’... GlobeNewswire Inc. - 10/2/2019 7:00:00 AM
Anavex Life Sciences Presented at the 6th Annual European Rett Syndrome Conference Preliminary Clinical Efficacy Data from th... GlobeNewswire Inc. - 9/27/2019 3:00:00 AM
Anavex Life Sciences to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference GlobeNewswire Inc. - 9/26/2019 7:00:00 AM
Notice of Effectiveness (effect) Edgar (US Regulatory) - 9/23/2019 6:35:19 AM
Anavex Life Sciences to Present at the Ladenburg Thalmann 2019 Healthcare Conference GlobeNewswire Inc. - 9/18/2019 7:00:00 AM
Post-effective Amendment to Registration Statement (pos Am) Edgar (US Regulatory) - 9/17/2019 5:16:10 PM
CLS Holdings (CLSH) $1.15 Price Target - MASS Approval for Recreational License InvestorsHub NewsWire - 9/17/2019 7:17:00 AM
Withdrawal of Registration Statement (ammendment) (aw) Edgar (US Regulatory) - 9/16/2019 4:17:42 PM
Anavex Life Sciences Announces Preliminary Clinical Efficacy Data of its U.S. Phase 2 Clinical Trial of ANAVEX®2-73 in Patie... GlobeNewswire Inc. - 9/16/2019 7:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/13/2019 5:11:08 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 9/13/2019 5:07:24 PM
Securities Registration Statement (simplified Form) (s-3/a) Edgar (US Regulatory) - 9/13/2019 5:02:44 PM
Anavex Life Sciences to Present at the Janney Healthcare Conference 2019 GlobeNewswire Inc. - 9/5/2019 7:00:00 AM
Anavex Life Sciences Announces Initiation of the EXCELLENCE ANAVEX®2-73-RS-003 Clinical Study in Pediatric Patients with Ret... GlobeNewswire Inc. - 9/4/2019 7:00:00 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 8/7/2019 4:07:28 PM
Anavex Life Sciences Reports Fiscal 2019 Third Quarter Financial Results And Provides Clinical Study Updates GlobeNewswire Inc. - 8/7/2019 7:00:00 AM
Anavex Life Sciences to Announce Fiscal 2019 Third Quarter Financial Results on Wednesday, August 7th, 2019 GlobeNewswire Inc. - 8/2/2019 7:00:00 AM
jtsmgoblue   Monday, 07/08/19 03:22:04 AM
Re: None
Post # of 231333 
So, I’m in or about to enter into negotiations with a potential suitor(s). I’ve got a truly disruptive molecule that some might tout as the next aspirin in terms of reach. I’m a micro biotech with about 25 key people, nearly all are executive level with medical type backgrounds. I’m not vertically integrated as i’m in development mode with a number of trials going in. i’m patent protected for at least 12 years and potential indications for my lead moecule are boundless. In fact, i’ve got a portfolio of products that could disrupt some key players in my industry. For a micro bio i’ve got a clean balance sheet, cash for two years and lifeline to sustain existing operations for a few more if necessary.

I’ve looked at my core competency and leverage as i’m about to enter negotiations:

- leadership team -check
- disruptive products-check
- trials funded-check
- peer acceptance -check
- patent protected -check
- market reach and depth -check
- fortress balance sheet - check
- cash infusion lifeline to sustain operations- check
- low outstanding shares -check
- fda or regulatory approval -
- vertically integrated or ability to get there -

seems i have two items to close. how to close those gaps to magnify my negotiating leverage?

fda or regulatory approval - trial readouts due out shortly (they dictate if approval forthcoming), some models say i’m nearly at 80% probability for approval

vertically integrated or ability to get there - guess i need the potential to raise big time cash to fund my growth. my key advisors, industry finance guys and lawyers all agree I need to seek a shelf offering with SEC. No need to execute but just in case those trial results come back favorable.

Wow looks like i’ve got All boxes checked. I’m now fully prepared to commence serious negotiations. i’ve got leverage in all competencies. Hope the negotiations yield the right offer. If not, i just walk away and on to plan B.

Anavex leadership is brilliant. Absolutely brilliant.







Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist